BRAF and metastatic melanoma: This model looked only at the direct patient-level clinical benefits of treatment, and does not account for the value of information gained from the development and use of these treatments to inform future treatments for metastatic melanoma, other BRAF-mutated cancers, or other mutation-specific targeted therapies.